Akshay Flora
Sydney, NSW, Australia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications
The Clinical and Molecular Response of Pyoderma Gangrenosum to IL-23 Blockade: Result from a Proof-of-Concept Open-Label Clinical Trial.
Journal: The Journal of investigative dermatology
Published: July 15, 2024
Response to adalimumab in Caucasian and Asian patients with hidradenitis suppurativa: A retrospective cohort study of an Australian cohort stratified by patient-reported ethnicity.
Journal: The Australasian journal of dermatology
Published: March 24, 2024
Diagnostic Accuracy of a Questionnaire Screening Test in Assessing the Prevalence of Hidradenitis Suppurativa in Sydney, Australia.
Journal: Dermatology (Basel, Switzerland)
Published: January 20, 2024
Understanding multi-kinase inhibitor-associated cutaneous ulcers may provide molecular insights into the aetiology of pyoderma gangrenosum: A comment on Jeon et al.
Journal: The Australasian journal of dermatology
Published: October 02, 2023
The serum proteome of pyoderma gangrenosum is more expansive than that of hidradenitis suppurativa.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: August 25, 2023
Alterations to the Hidradenitis Suppurativa Serum Proteome with Spleen Tyrosine Kinase Antagonism: Proteomic Results from a Phase 2 Clinical Trial.
Journal: The Journal of investigative dermatology
Published: August 13, 2023
Rapid Attenuation of B-Cell and IFN-γ-Associated Chemokines in Clinical Responders to Jak Inhibition with Upadacitinib in Hidradenitis Suppurativa.
Journal: The Journal of investigative dermatology
Published: June 20, 2023
Mast cells are upregulated in hidradenitis suppurativa tissue, associated with epithelialized tunnels and normalized by spleen tyrosine kinase antagonism.
Journal: Experimental dermatology
Published: March 30, 2023
A proof-of-concept open-label clinical trial of spleen tyrosine kinase antagonism using fostamatinib in moderate-to-severe hidradenitis suppurativa.
Journal: Journal of the American Academy of Dermatology
Published: January 30, 2023
Baseline clinical, hormonal and molecular markers associated with clinical response to IL-23 antagonism in hidradenitis suppurativa: A prospective cohort study.
Journal: Experimental dermatology
Published: January 24, 2023
Treatment of alopecia areata with the janus kinase inhibitor upadacitinib: A retrospective cohort study.
Journal: Journal of the American Academy of Dermatology
Published: September 12, 2022
Last Updated: 09/26/2026